Phase 2 prospective study of the efficacy of nab-paclitaxel, carboplatin and bevacizumab for the treatment of stage 3B/4 non-squamous cell and non-small cell lung cancer
Not Applicable
- Conditions
- on-squamous cell and non-small cell lung cancer
- Registration Number
- JPRN-UMIN000024610
- Lead Sponsor
- niversity of Fukui
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Brain metastasis accompnied by significant symptoms. 2) Hemoptysis 3) Allergy or hypersensitibity against the medicines in this trial or albumin. 4) Peripheral neuropathy (grade 2 or more) before the treatment. 5) Uncontrolled effusion. 6) Palliative radiation within 2 weeks. 7) Operation within 4 weeks. 8) Active double cancer 9) High body temperature (38 degrees Celsius and more). 10) Severe complications. 11) Anti-coagulation therapy 12) Pregnant woman 13) HBs antigen positive 14) The subjects whom the doctor excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progressin free survival after the first line chemotherapy, the combination of nab-paclitaxel, carboplatin and bevacizumab.
- Secondary Outcome Measures
Name Time Method Overall survival,progressin free survival after the maintenance therapy, response rate, and safety